Plasma PACAP levels were significantly lower in PD patients without deep brain stimulation (DBS) therapy compared to healthy controls, and DBS–treated patients had significantly higher plasma PACAP levels compared to PD patients who had not received DBS therapy. Here, ADCYAP1 is linked to Parkinson disease.